Hi Dr. Fauci:

I have been a long time admirer of you in the field of modern medicine. This question I have relates to the current Coronavirus circulating around the world. For many years I have informed people that the ways a virus can be passed from person to person isn’t always by a sneeze, cough or by touching someone’s face with their hands. Has anyone in your medical community thought that if someone were smoking and was an infected person that once they expelled the smoke particles into the air that those micro smoke particles may contain viruses that were in the respiratory system of an infected person. Everyone I mention this to don’t believe that this is possible. What are your thoughts on this matter? If so why hasn’t the medical community warned the public about this possibility as I stay away from all establishments that allow smoking on their premises.

Thank you,

Daniel Gagnon
Here is the reason for the confusion.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RABIN, RONI <roni.rabin@nytimes.com>
Sent: Monday, February 24, 2020 2:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: interview with Dr Fauci

I'm sorry -- I thought you had canceled this time this morning when you said you needed to reschedule. I'm so sorry. I'm in the middle of a meeting with editors at the Times about coronavirus coverage.

On Mon, Feb 24, 2020 at 2:42 PM Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

Hi Roni,
We just tried calling you at (b) (6) for our 2:30pm ET interview with Dr. Fauci. Please give us a call as soon as possible at (b) (6).

Thank you,
Kim

Kim Barasch [c]
Office of the Director
National Institute of Allergy & Infectious Diseases
(b) (6)
From: Conrad, Patricia (NIH/NIAID) [E]  
Sent: Friday, February 21, 2020 4:30 PM  
To: [Redacted]  
Cc: Deatrick, Elizabeth [NIH/NIAID] [C] <[Redacted]>; Robinson, Whitney [NIH/NIAID] [C]  
Subject: interview with Dr Fauci

Dr Fauci can be available for your interview as per below on Monday Feb 24th at 2:30 pm ET – 3:00 pm ET. Please let us know asap if that time works. The number to call for the interview will be [Redacted]

Thank you,
-patty

Roni Rabin  
New York Times  
[Roni.rabin@nytimes.com](mailto:Roni.rabin@nytimes.com)  
Seeking Phone interview  
Subject: asymptomatic transmission of coronavirus

Patricia L. Conrad  
Public Health Analyst and  
Special Assistant to the Director  
National Institute of Allergy and Infectious Diseases  
The National Institutes of Health  
31 Center Drive, MSC 2520 - Room 7A03  
Bethesda, Maryland 20892  
[Redacted]  
301-496-4409 fax

Disclaimer:  
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

Roni Caryn Rabin  
New York Times Staff Writer  
(212) 556-8314
Cell: (b) (6)
And per CDC -- requires airborne precautions
https://www.cdc.gov/infectioncontrol/basics/transmission-based-precautions.html

Table 2
Overview of the evidence on transmission routes of respiratory viruses based on experimental data and the transmission route according to infection prevention guidelines

<table>
<thead>
<tr>
<th>Virus</th>
<th>Virus family</th>
<th>Transmission route</th>
<th>Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parainfluenza virus</td>
<td>Paramyxoviridae</td>
<td>Limited data, contact (by fomites) [83, 84]</td>
<td>Contact [3, 109], droplet [3, 109-111], aerosol [3, 109].</td>
</tr>
<tr>
<td>HMPV</td>
<td>Pneumoviridae</td>
<td>Limited data, contact (by fomites) [38]</td>
<td>Contact [3, 110].</td>
</tr>
<tr>
<td>RSV</td>
<td>Pneumoviridae</td>
<td>Contact [89, 88], droplet [88], aerosol [90, 91].</td>
<td></td>
</tr>
<tr>
<td>HCoV</td>
<td>Coronaviridae</td>
<td>Limited data, contact (by fomites) [65-67]</td>
<td>Contact [3, 110], droplet [3, 110], aerosol [3, 110].</td>
</tr>
<tr>
<td>MERS-CoV</td>
<td>Coronaviridae</td>
<td>Contact [70] &quot;79, 101], droplet [70, 79], aerosol [79, 101]</td>
<td>Contact [3, 110, 111], aerosol [3, 110, 111], aerosol [3, 110, 111].</td>
</tr>
<tr>
<td>SAR-CoV</td>
<td>Coronaviridae</td>
<td>Contact [35, 56, 57, 59]</td>
<td>Contact [3, 110, 111].</td>
</tr>
<tr>
<td>Rhinovirus</td>
<td>Picornaviridae</td>
<td>Droplet/aerosol [35, 56, 57, 59]</td>
<td>Contact [3, 110, 111].</td>
</tr>
</tbody>
</table>

Disclaimer: Any third-party material in this email has been shared under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.
Johan:

Thanks for the note. I enjoyed and learned from your presentation this morning. The best way to keep in touch with NIAID would be through Emily and Barney.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4084
FAX: (301) 496-4409
E-mail:?

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage device. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Dear Emily,

Dear Dr. Fauci,

First of all, I want to thank NIAID and its team for spending time with us going through the Janssen plans for Ad 26 COVID-19 vaccine development.

In follow up of our call earlier today, please find herewith the key action points I noted from our discussion. I would welcome your perspectives/comments, as well as the best way to keep in touch with NIAID.

Looking forward to your feedback,
Best regards,

Johan

Johan Van Hoof, M.D.

Managing Director, Janssen Vaccines and Prevention B.V.
Global Therapeutic Area Head IDV, Vaccines, Janssen Pharmaceuticals R&D

Phone: (b) (6) Fax: +32 14 60 2841
E-mail: (b) (6)

Assistant
Phone: (b) (6)

Follow Up to Ad26 COVID-19 call with NIAID; February 24th 2020
You are correct.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
FAX: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E]
Sent: Monday, February 24, 2020 11:51 AM
To: Fauci, Anthony (NIH/NIAID) [E]; Eisinger, Robert (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]
Cc: (b)(6)
Subject: ASF ------ NEJM commentary -- change title?

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 16:51:09 +0000
To: Faye Li
Cc: Billet, Courtney (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Interview Request from China

Faye:

Thank you for your note. Please send me your questions by e-mail and I will try to answer them by e-mail.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4402
FAX: (301) 496-4409
E-mail: anthony.fauci@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Faye Li
Sent: Monday, February 24, 2020 11:41 AM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Interview Request from China

Dear Dr. Fauci,

I'm Faye Li, journalist from the Portrait, a national magazine in China. My beat is science and technology. Since the outbreak of the 2019 novel coronavirus (COVID-19) in China, I'm covering feature stories about the outbreak, hoping to explain to readers what it is, especially since the virus is evolving daily at an unexpected high speed, and in so many confusing ways.

Now in China we are getting conflicting information about the new virus and thus become confused about it. For example, we are seeing more and more cases that a patient with negative test results for 2 non-continuous days, still infected with the virus and tested positive afterwards. It makes the treatment really difficult because it seems hard to determine whether the patient is fully cured or not. Since you are an experienced immunologist, I'm wondering if you could share your insights with the Chinese readers and take an interview. The Interview could be via phone or email, whichever works fine for you.
If possible, I’d love to send you the questions before we talk. Since we have time difference, I might not be available during the early afternoon (your time) but I could make it in the morning, noon and maybe late in the afternoon and evening (your time).

I’m sorry for bothering you on this subject, but we face severe difficulty in understanding this new virus and taking measures properly. We have quite limited sources and perspectives for understanding this new virus. However, as a science reporter, I believe in a crisis of public health, the information is the key for the public. They should have the opportunity to hear more perspectives from different specialists. Since you are experienced in fighting against so many viruses, especially SARS, I believe your opinions will be inspiring to the readers.

It would be of great help and great honor for us to invite you for an interview. A phone call interview would be preferred but if time doesn’t work for you, is it possible for you to reply via email? I’ll list all the questions in detail.

I could be reached by (b) or (b) I’m looking forward to your reply.

Best wishes,

Faye

The Portrait
Beijing, China
Cristina, please.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: 
FAX: (301) 496-4409
E-mail: 
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Is this a friend or do u just want to pass to Cristina. Pls advise

Sent from my iPhone

Begin forwarded message:

From: "Haskins, Melinda (NIH/NIAID) [E]"
Date: February 24, 2020 at 10:40:37 AM EST
To: "Conrad, Patricia (NIH/NIAID) [E]"
Cc: "Harris, Kara (NIH/NIAID) [E]"
Subject: FW: Call for Dr. Fauci

From: Harris, Kara (NIH/NIAID) [E]
Sent: Monday, February 24, 2020 10:39 AM
Hi, Kim—

I spoke to Dr. Jacobs directly. He said that Dr. Michael Lockshin is a good friend/fellow Cornell graduate (Dr. Jacobs also noted he went to Cornell) and gave him Dr. Fauci’s number.

Dr. Jacobs and Dr. Alexander Tarakhovsky, a virologist at The Rockefeller Institute, would like to speak to Dr. Fauci about the coronavirus. They have a theory that there may be yeast involved because it is sticky and perhaps it came from the Chinese government. They want to share their ideas and perhaps start a U.S. government effort “similar to The Manhattan Project.” They do not want funding.

I thanked Dr. Jacobs for sharing his ideas and stated that I would pass along the message. Should Dr. Fauci wish to speak to them, Dr. Jacobs can be reached at [redacted]

Please let me know if you have any questions.

Thanks,

Kara

---

Hi, Kim—I got some additional information from Dr. Michael Jacobs office. He is a dermatologist in New York City and said that Dr. Fauci is expecting his call. The secretary provided no further information.

Dr. Michael Jacobs

Thank you.

Claire A. McCullough
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane, Rm. 6F27 – MSC 9805
Bethesda, MD 20892
Tel: [redacted]

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy
and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID.
fyi

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
E-mail: (301) 496-4409

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: New England Journal of Medicine <onbehalfof@manuscriptcentral.com>
Sent: Monday, February 24, 2020 10:00 AM
To: Fauci, Anthony (NIH/NIAID) [E] (6); Lane, Cliff (NIH/NIAID) [E] (6); Redfield, Robert R. (CDC/OD) [E] (6)
Subject: New England Journal of Medicine 20-02387

Dear Dr. Fauci,

Thank you for the article, "COVID-19: Navigating the Unchartered," which the Journal is pleased to accept for publication.

This acceptance is made with the understanding that neither the article itself nor any part of its essential substance, tables or figures has been published or will be submitted for publication elsewhere before it appears in the Journal. The acceptance is also made with the understanding that all the authors, the data, and its presentation meet the requirements as described in the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (www.icmje.org).

Please note that the acceptance of your commentary should be considered confidential information to be shared only with your coauthors until its final publication. To ensure that no news reports about the article appear prematurely in any form, do not speak to the media, hold press conferences, or issue news releases about your paper before the week of publication. You must receive an explicit commitment to withhold release of the information until the embargo is lifted at 5:00 p.m. (Eastern Time in the United States) on the day before the date of publication. If there are any questions about this policy, you should discuss them with the Editor.

We assume that financial relationships creating possible conflicts of interest for all authors have been fully disclosed to the Editor, including (but not limited to) any relevant relationships listed in the Open Payments database at
Please visit https://openpaymentsdata.cms.gov/search/physicians/by-name-and-location for physicians practicing in the United States. For information on what would qualify as a 'relevant' disclosure, please review the instructions on page 1 of your disclosure form.

Authors are reminded that all material published in the Journal is copyrighted by the Massachusetts Medical Society, that by agreeing to have their manuscript published in the Journal they grant to the Society full right and authority to secure copyright for the full term and any renewals or extensions thereof, and that permission for reprinting must be obtained in writing from the Journal.

The Journal will edit your manuscript in accordance with its established style. You will receive a proof of the edited manuscript by e-mail; the proof stage will be your next opportunity to make changes. For important information about production and proofs, see the attached document. In the meantime, please do not make any changes or send any new material to us. Thank you for your contribution to the Journal.

Sincerely yours,

Eric J. Rubin, MD, PhD
Editor-in-Chief

New England Journal of Medicine
10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
http://www.nejm.org
Ming:
Thank you for your note and offer to help. I will ask my Staff Assistant, Kim Barasch, to set up a brief call for you to relate your impressions to me.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: __________________________
FAX: (301) 496-4409
E-mail: __________________________

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: __________________________
Sent: Sunday, February 23, 2020 7:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] __________________________
Cc: __________________________
Subject: COVID-19 Quarantine

Dear Dr. Fauci,

My name is Ming Lei, a Division Director at the NIGMS. I am writing to you as a private citizen, to thank you for your leadership in yet another public health emergency, and to make myself available to you if you have the time for my in-person observations of the COVID-19 caused quarantine in Hubei Province, China, the evacuation of Americans; and the quarantine in the US.

As the virus still roams around, and a possibility of causing a pandemic, I want to let you know that I am willing to share with you my direct observations in case such information is of value in the developing of our responses going forward, which you will undoubtedly playing a critical role.

I will send you a reminder through my NIH email account, in case this message is put into the junk mail folder.
Sincerely,
Looks fine to me.

Renate is asking that I confirm that Dr. Collins’ changes (tracked in attachments) sync with what we’ve been saying. They look ok to me. What say you?
Hi all,

Nicely done, Renate. I made a few edits in two of the documents, see attached.

---

From: Myles, Renate (NIH/OD) [E]  
Sent: Sunday, February 23, 2020 8:56 PM  
To: Fauci, Anthony (NIH/NIAID) [E]  
Collins, Francis (NIH/OD) [E]  
Tabak, Lawrence (NIH/OD) [E]  
Gilman, James (NIH/CC/OD) [E]  
Cc: Burklow, John (NIH/OD) [E]  
Hallett, Adrienne (NIH/OD) [E]  
Allen-Gifford, Patrice (NIH/OD) [E]  
Billet, Courtney (NIH/NIAID) [E]  
Davey, Richard (NIH/NIAID) [E]  
Palmore, Tara (NIH/CC/OD) [E]  
Cohen, Justin (NIH/CC/OD) [E]  

Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Thanks, all.  

Latest rollout, all staff and statement are attached.

Best,  
Renate

---

From: Fauci, Anthony (NIH/NIAID) [E]  
Sent: Sunday, February 23, 2020 8:15 PM  
To: Myles, Renate (NIH/OD) [E]  
Collins, Francis (NIH/OD) [E]  
Tabak, Lawrence (NIH/OD) [E]  
Gilman, James (NIH/CC/OD) [E]  
Cc: Burklow, John (NIH/OD) [E]  
Hallett, Adrienne (NIH/OD) [E]
The rollout plan looks fine except that I would include .

Thanks,
Tony

Good evening:

Attached for your review are draft materials to communicate NIH’s preparation for potential receipt of patients with COVID-19 to the NIH Clinical Center (timing TBD), including:

1. Rollout plan
2. All staff email
3. Statement

These materials were reviewed by Rick Davey, Tara Palmore, and Courtney Billet. I am developing a list of potential Qs and will work with CC and NIAID folks to develop responses, but I wanted to get these products into review in the interest of time.

Best,
Renate

Renate Myles, MBA
Deputy Director for Public Affairs
Office of Communications and Public Liaison
National Institutes of Health
Lorenzo

Thanks for the note. Unfortunately, I cannot be of any help to you since I myself have no access to this equipment. The best person to contact would be Dr. Robert Kadlec of ASPR at HHS.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4000
FAX: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Dear Dr. Fauci,

I apologize in advance if I write you directly to ask this question. I know you are super busy but I thought you could provide some guidance on someone I could contact about this matter.
I know this seems a very technical question and I appreciate you have many other things on your plate, so I hope you don't mind if I decided to reach you out. I do know that Filippo and his team will be very grateful for any guidance that they could receive.

Thanks in advance-
Lorenzo

Lorenzo Leggio, M.D., Ph.D.
Senior Investigator (Clinical), NIDA IRP and NIAAA DICBR
Chief, Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, NIDA IRP and NIAAA DICBR
Associate Director for Clinical Research, Medication Development Program, NIDA IRP
Senior Medical Advisor to the Director, NIAAA
National Institutes of Health

10 Center Drive (10CRC/15330) Room 1-5429
Bethesda, MD 20892-1108

251 Bayview Blvd, Room 01A844
Baltimore, MD 21224

Office Phone: (b) (6) (Bethesda); (b) (6) (Baltimore)
Cell: (b) (6)
E-mail: (b) (6)

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.
Thanks, Stewart. We will do it again after Cliff returns from China and finishes his 14 day self-quarantine.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b)(6)
FAX: (301) 496-4409
E-mail:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Thank you—he is grateful for your help, Tony. He is in a unwindable situation but he is doing what is right and with integrity. I really appreciate it.

S

On Feb 24, 2020, at 7:23 AM, Fauci, Anthony (NIH/NIAID) [E] wrote:

Stewart:

Here is another article in which I strongly support Tedros.

Tony
From: John Lauerman |BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>
Sent: Monday, February 24, 2020 7:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)
Subject: Our story today

Hi Dr. Fauci: here's our story on Tedros today, in case you haven't seen it.


Thanks again for all your help with this one. Hope we get a chance to talk again soon.
Regards, JL

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel. +44 (0) 2035 251028 cell (b)(6)
http://www.bloomberg.com
http://www.bloomberg.com/prognosis
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 12:24:01 +0000
To: John Lauerman
Subject: RE: Our story today

Thanks, John.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4040
FAX: (301) 496-4409
E-mail: fauci@nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: John Lauerman (BLOOMBERG/NEWSROOM;) <jlauerman@bloomberg.net>
Sent: Monday, February 24, 2020 7:04 AM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Our story today

Hi Dr. Fauci: here's our story on Tedros today, in case you haven't seen it.


Thanks again for all your help with this one. Hope we get a chance to talk again soon.
Regards, JL

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel. +44 (0) 2035 251028 cell: ????
http://www.bloomberg.com
http://www.bloomberg.com/prognosis
Cristina:

Please see if we can engage this person (Richard Tubb) and see what he has to offer. He used to be the White House physician.

Thanks,

Tony

---

Steve:

Thanks for the note. I do indeed know Dr. Tubb. He sent me similar material and I am going to connect him with our program people here at NIAID to see if we can help in any way.

Best regards,

Tony

---

Tony,

I expect you know Dr. Richard Tubb. He and I worked closely together in the White House 18 years ago. I have a lot of confidence in his judgment, and therefore am forwarding the materials he sent me for your consideration.

I know nothing about the technologies involved, but I know this is a time to write off no good options.

Warm regards,
Steve

Sent from my iPhone

Begin forwarded message:

From: Richard Tubb
Date: February 24, 2020 at 8:47:23 PM EST
To: "Biegun, Stephen E" , Robert Kadlec
Subject: ACT Additional reading material and developments
Let us discuss

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gatti, Philip <b>(b) (6)>
Sent: Monday, February 24, 2020 2:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] <b>(b) (6)>
Subject: FW: chloroquine in COVID-19

Dear Dr. Fauci,

Is there any indication/data to substantiate this claim from China (attached publication) that chloroquine/hydroxychloroquine can decrease COVID-19 infections and lung disease?

Thank you,
Philip Gatti, Ph.D.
Pharmacologist
FDA
CDER
OND
Silver Spring, MD

NIH-001430
Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted]
FAX: (301) 496-4409
E-mail: [redacted]

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gatti, Philip
Sent: Monday, February 24, 2020 3:05 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: chloroquine in COVID-19

Tony,
Thanks for the quick response. There are data from 2005 showing inhibition of SARS infection and spread from 2005. Please see attached.
Regards,
Phil

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, February 24, 2020 3:00 PM
To: Gatti, Philip
Cc: Lane, Henry C (NIH); Cassetti, Cristina G (NIH); Erbelding, Emily J (NIH)
Subject: RE: chloroquine in COVID-19

Phil:
There are no data in this brief report and so I have no way of evaluating their claim. There are a lot of these types of claims going around. I would love to see their data.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gatti, Philip <(b) (6)>
Sent: Monday, February 24, 2020 2:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: chloroquine in COVID-19

Dear Dr. Fauci,
Is there any indication/data to substantiate this claim from China (attached publication) that chloroquine/hydroxychloroquine can decrease COVID-19 infections and lung disease?
Thank you,
Philip Gatti, Ph.D.
Pharmacologist
FDA
CDER
OND
Silver Spring, MD

(b) (6)
Yes-- that was the main thing-- but any other issues that you can think of in our space?

Thanks

Get Outlook for iOS
From: Tabak, Lawrence [NIH/OD] [E] (b)(6)>
Sent: Wednesday, February 26, 2020 1:57 PM
To: Fauci, Anthony [NIH/NIAID] [E] (b)(6); Hallett, Adrienne [NIH/OD] [E] (b)(6); Conrad, Patricia [NIH/NIAID] [E] (b)(6)
Subject: Fwd: URGENT- Need your input

I will join call- anything you want brought up?
Larry

Get Outlook for iOS

From: Pollard, Ashton (OS/IOS) (b)(6)>
Sent: Wednesday, February 26, 2020 1:44:56 PM
To: Mango, Paul (HHS/IOS) (b)(6); Lenihan, Keagan (FDA/OC) (b)(6); Tabak, Lawrence (NIH/OD) [E] (b)(6); McGowan, Robert (Kyle) (CDC/OD/OCS) (b)(6); Shuy, Bryan (OS/ASPR/IO) (b)(6); Zebley, Kyle (HHS/OS/OGA) (b)(6); Charrow, Robert (HHS/OGC) (b)(6)
Subject: RE: URGENT- Need your input

Hi All,

I am about to send this invite. Please confirm your attendance via email or by accepting the calendar invite.

Thank you,
Ashton

-----Original Message-----
From: Mango, Paul (HHS/IOS) (b)(6)
Sent: Wednesday, February 26, 2020 1:43 PM
To: Lenihan, Keagan (FDA/OC) (b)(6); Tabak, Lawrence (NIH/OD) [E] (b)(6); McGowan, Robert (Kyle) (CDC/OD/OCS) (b)(6); Shuy, Bryan
Subject: URGENT- Need your input

Team- Urgent, how priority request:

Ashton will invite you to a 230pm call to discuss. Please organize your responses into bullet points to discuss with the group.

Sent from my iPhone
Here are my edits.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

These are Sec Azar’s remarks for press tonight. (Plan still evolving.)
They are asking for our comments back by 2:45 pm. New content is highlighted to make it easier on reviewers.
We’re sending your talking points down there momentarily.
Hi all,

Attached is a draft of the Secretary's remarks for this evening's potential press briefing. Some of this is rote/repeated from yesterday or this morning's testimony; I have put the new content in **yellow** to accelerate review.

**Please let me know if you have edits to this by 2:45 PM.**

Thank you!

Best,

Patrick
I do not have time for this. Sorry.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (301) 496-4409  
E-mail:  

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E]  
Sent: Tuesday, February 25, 2020 10:08 PM  
To: Fauci, Anthony (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]  
Cc:  
Subject: Fwd: For review by 10:00 AM Weds: Peter Navarro coronavirus op-ed

This is an oped for Peter Navarro. We are asked for comments by 10am Weds.

(Complicating things a little, he was apparently just on with Tucker Carlson stating parts of it verbatim. So, hopefully this is accurate!)

From: "Brennan, Patrick (OS/ASPA)"  
Date: Tuesday, February 25, 2020 at 8:27:03 PM  
To: "Conrad, Patricia (NIH/NIAID)"; "Bonds, Michelle E. (CDC/OD/OADC)"; "Galatas, Kate (CDC/OD/OADC)"; "Billet, Courtney (NIH/NIAID)"; "Michael, Gretchen (OS/ASPR/OEA)"; "Janik, Heather (FDA/OC)"; "Caliguiri, Laura (FDA/OC)"; "Lepore, Loretta (CDC/OD/OC5)"; "Stimson, Brian (HHS/OGC)"; "Arbes, Sarah (HHS/ASL)"; "Morse, Sara (HHS/OSID)"
Hi all,

Attached is a draft op-ed from the WH’s Peter Navarro regarding the administration’s coronavirus response – covering PPE, vaccines, therapeutics, and diagnostics.

There is a lot going on here so we’d like to have edits/recommendations/affirmative clearance from FDA, CDC, NIAID, ASFR, and ASPR.

Please send edits to me and Tim Foster by 10:00 AM tomorrow (Wednesday). Thank you!

Best,
Patrick
Thanks, Larry!

-----Original Message-----
From: Tabak, Lawrence (NIH/OD) [E] [(b) (6)]
Sent: Tuesday, February 25, 2020 9:01 PM
To: Fauci, Anthony (NIH/NIH) [E] [(b) (6)]
Subject: FW: LHHS appropriators coronavirus supplemental brief 3:30p Wednesday

Tony,
I will be able to do this, hopefully we can move this back in the correct direction.
Larry

On 2/25/20, 9:00 PM, "Cochran, Norris (HHS/ASFR)" [(b) (6)] wrote:

Correction, [(b) (6)]. Thank you in advance.

Norris

> On Feb 25, 2020, at 8:55 PM, Cochran, Norris (HHS/ASFR) [(b) (6)] wrote:
> > Dr. Tabak, Neil - would you be available to brief [(b) (5)] We would have CDC on the line as well. ASPR by phone or in person. We will be in person. Please let me know either way. Thank you in advance.
> > Norris
Rick/Tara:
   Please give me a call (b) (5). If during business hours, please call my office at (b) (6) If in the evening/night call my cell phone at (b) (6). My home phone is (b) (6).
Thanks,
Tony

From: Tabak, Lawrence [NIH/OD] [E]  
Sent: Monday, February 24, 2020 10:40 PM  
To: Kadlec, Robert (OS/ASPR/IO)  
  <(b) (6)>, Stecker, Judy (OS/IOS)  
Cc: Harrison, Brian (HHS/IOS)  
  (b) (6), Fauci, Anthony (NIH/NIAID) [E]  
  (b) (6), Palmore, Tara (NIH/CC/OD) [E]  
  (b) (6), Yeskey, Kevin (OS/ASPR/IO)  
  (b) (6), Lee, Scott (OS/ASPR/EMMO)  
Subject: Re: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

thanks

From: "Kadlec, Robert (OS/ASPR/IO)"  
Date: Monday, February 24, 2020 at 10:37 PM  
To: "Tabak, Lawrence (NIH/OD) [E]"  
  (b) (6), "Stecker, Judy (OS/IOS)"  
  (b) (6)  
Cc: "Harrison, Brian (HHS/IOS)"  
  (b) (6) Anthony Fauci  
  (b) (6) "Palmore, Tara (NIH/CC/OD) [E]"  
  (b) (6), "Yeskey, Kevin (OS/ASPR/IO)"  
  <Kevin.Yeskey@hhs.gov>, "Greene, Jonathan (OS/ASPR/EMMO)"  
  (b) (6), "Lee, Scott (OS/ASPR/EMMO)"  
Subject: RE: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Larry would be  
(b) (6). Best Bob

From: Tabak, Lawrence [NIH/OD] [E]  
Sent: Monday, February 24, 2020 10:28 PM  
To: Kadlec, Robert (OS/ASPR/IO)  
  (b) (6), Stecker, Judy (OS/IOS)  
Cc: Harrison, Brian (HHS/IOS)  
  (b) (6), Fauci, Anthony (NIH/NIAID) [E]  
  (b) (6), Palmore, Tara (NIH/CC/OD) [E]  
  (b) (6), Yeskey, Kevin

NIH-001380
From: "Kadlec, Robert (OS/ASPR/IO)" <kadlec_robert@health.gov>
Date: Monday, February 24, 2020 at 10:26 PM
To: "Stecker, Judy (OS/IOS)"
Cc: "Harrison, Brian (HHS/IOS)"

Subject: FW: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Judy for action

From: Kadlec, Robert (OS/ASPR/IO)
Sent: Monday, February 24, 2020 10:19 PM
To: Harrison, Brian (HHS/IOS); Stecker, Judy (OS/IOS); Mango, Paul (HHS/IOS); Murphy, Ryan (OS/ASPA); Arbes, Sarah (HHS/ASL); Faucin, Anthony (NIH/OD); Tabak, Lawrence (NIH/OD); Redfield, Robert R. (CDC/OD); McGowan, Robert (Kyle) (CDC/OD/OCS); Trueman, Laura (HHS/IEA); Moughalian, Jen (HHS/ASFR); Johnston, Darcie (HHS/IEA); Lee, Scott (OS/ASPR/EMMO); Yeskey, Kevin (OS/ASPR/O); Waters, Cicely (OS/ASPR/OEA); Shuy, Bryan (OS/ASPR/O); Greene, Jonathan (OS/ASPR/EMMO); Imbrie, Samuel (OS/ASPR/SIIM); Herrmann, Jack (HHS/ASPR/DPP); Ferro, Phil J. EOP/NSC; Ruggiero, Anthony J. EOP/NSC <cavanaugh_brian_j@health.gov>

Subject: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB
Importance: High

This evening, we were advised by the State of California that 4 passengers from the Diamond Princess tested positive by the CDC for COVID-19.
One individual who tested positive by the CDC had been tested positive in Japan and is already in hospital in CA.

We are developing the following possible Courses of Action as the State of CA cannot absorb these 3 additional asymptomatic individuals:
Jen:

I had changed the (b) (5)

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [ ] (b) (6)
FAX: (301) 496-4409
E-mail: [ ] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

From: Moughalian, Jen (HHS/ASFR) (b) (6)
Sent: Monday, February 24, 2020 1:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6); Shuy, Bryan (OS/ASPR/IO) (b) (6); Kadlec, Robert (OS/ASPR/IO) (b) (6); Grigsby, Garrett (HHS/OS/OGA) (b) (6); Zebley, Kyle (HHS/OS/OGA) (b) (6); Lenihan, Keagan (FDA/OC) (b) (6); Redfield, Robert R. (CDC/OD) (b) (6)
Cc: Cochran, Norris (HHS/ASFR) (b) (6); Cabezas, Miriam (HHS/ASFR) (b) (6); Hittle, Taylor (HHS/ASFR) (b) (6)
Subject: RE: Close Hold Review - Send comments by 1:40 pm

Thanks for the quick response!

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Monday, February 24, 2020 1:42 PM
To: Moughalian, Jen (HHS/ASFR) (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6); Shuy, Bryan (OS/ASPR/IO) (b) (6); Kadlec, Robert (OS/ASPR/IO) (b) (6); Grigsby, Garrett (HHS/OS/OGA) (b) (6); Zebley, Kyle (HHS/OS/OGA) (b) (6); Lenihan, Keagan (FDA/OC) (b) (6);
Jen:

See my suggested edits in red.

Thanks,

Tony

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

---

From: Moughalian, Jen (HHS/ASFR) <b>(b)</b>
Sent: Monday, February 24, 2020 1:18 PM
To: McGowan, Robert (Kyle) (CDC/OD/OCS) <b>(b)</b>; Shuy, Bryan (OS/ASPR/IO) <b>(b)</b>; Kadlec, Robert (OS/ASPR/IO) <b>(b)</b>; Grigsby, Garrett (HHS/OS/OGA) <b>(b)</b>; Zebley, Kyle (HHS/OS/OGA) <b>(b)</b>; Fauci, Anthony (NIH/NIAID) [E] <b>(b)</b>; Lenihan, Keagan (FDA/OC) <b>(b)</b>; Redfield, Robert R. (CDC/OD) <b>(b)</b>
Cc: Cochran, Norris (HHS/ASFR) <b>(b)</b>; Cabezas, Miriam (HHS/ASFR) <b>(b)</b>; Hittle, Taylor (HHS/ASFR) <b>(b)</b>
Subject: Close Hold Review - Send comments by 1:40 pm
Importance: High

Close hold. Please see below draft OMB language for a possible emergency supplemental request. Due to the fast moving nature of this process, please send comments by 1:40 PM. Numbers are still under discussion, and we will share more info in the daily update.
Jen Moughalian
Assistant Secretary for Financial Resources (ASFR)
US Department of Health and Human Services
(6) (Office)
(6) (Cell)